RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Watson Imaging Care Advisor for Liver

Product
The name of the base system (platform): IBM Watson Health
Developers: IBM
Date of the premiere of the system: July, 2018
Branches: Pharmaceutics, medicine, health care

2018: Announcement of a product

In July, 2018 the American IBM IT corporation and the French developer of the contrast substances Guerbet announced creation of the software for diagnosis of cancer of liver. Developments are the cornerstone the algorithms of artificial intelligence taken from the IBM Watson Health platform.

The first joint product of IBM and Guerbet received the name Watson Imaging Care Advisor for Liver. He automatically reveals oncological diseases of a liver, defines their stages of development, keeps track of dynamics, makes recommendations about the most effective methods of treatment and controls therapy process.

IBM and the developer of contrast substances also created software for diagnosis of cancer of liver

Software is connected to systems computer and magnetic resonance imaging and also to other diagnostic equipment and tools helping doctors to make decisions.

IBM and Guerbet are also going to finish software that it was compatible to the most popular transmission systems and archivings of medical images (PACS). It becomes for the purpose of software integration with workflows of doctors and medical institutions.

It is supposed that Watson Imaging Care Advisor for Liver and other joint solutions of IBM and Guerbet will help doctors to reveal quicker cancer tumors and to make the correct plans of treatment, proceeding from features of course of a disease and specific features of an organism of patients.

In the press release of July 10, 2018 it is said that cancer of a liver is the second in prevalence cause of death from oncological diseases, and in the USA — the most fast-growing. About 83% of cases of primary cancer of liver are the share of developing countries. The liver is also the widespread place for metastases, especially in case of cancer of a gastrointestinal tract at which almost at a half of patients metastases develop.[1]

Notes